esketamine
New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression
May 21, 2019Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma
New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …
Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression
March 21, 2019Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs
The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …
Janssen’s party drug-based nasal spray becomes first new FDA-approved depression treatment in 30 years
March 6, 2019Research and Development, Sales and Marketing Janssen, Spravato, depression, esketamine, pharma
The field of depression therapy has seen its biggest leap forward in over three decades, the FDA approval of Janssen’s …
Top Ten most popular articles on Pharmafile.com this week!
February 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMR, Dame Sally Davies, FDA, FMD, antibiotic resistance, esketamine, falsified medicines, top 10
News that the FDA’s advisory panel had recommended Janssen’s intranasal esketamine spray Spravato as a treatment for treatment resistant depression, …
Janssen’s esketamine drug recommended by FDA panel for depression
February 13, 2019Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma
In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …
J&J’s ketamine-based antidepressant showed mixed success at Phase 3
May 8, 2018Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma
Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …
